Drug Therapy

Nanoparticle System Uses Light Waves to Target Release Site of Drug

By

Nanoparticles that release a drug only when exposed to near-infrared (NIR) light are a promising drug-delivery agent developed by Canadian researchers.

Nanoparticle Drug Delivery Aims to Control Pancreatic Tumor and Inhibit Escape Pathways

By

Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.

Natural Nanoparticles Effectively Deliver Drug Therapy in Resistant Lung Cancer

Natural Nanoparticles Effectively Deliver Drug Therapy in Resistant Lung Cancer

By

Exosome serves as a natural nanoparticle delivery system and achieves the same cancer-killing effect on drug-resistant lung cancer as current formulations of drug therapy with 50x less drug.

Progression-free Survival of Patients With Neuroendocrine Tumors Improved With Everolimus

By

A new analysis of a phase III trial of patients with neuroendocrine tumors that began in the gastrointestinal (GI) tract or at an unknown primary location found that progression-free survival was improved with everolimus by 6 to 8 months compared with placebo.

Link Between Obesity and Increased Risk for Colorectal Cancer May Be Therapy Target

Link Between Obesity and Increased Risk for Colorectal Cancer May Be Therapy Target

By

A drug currently approved for GI conditions may prevent the development of colorectal cancer, according to researchers who revealed a biological connection between obesity and increased risk for colorectal cancer.

Prescription Coverage Impacts Treatment Adherence in Breast Cancer, Even for Low-cost Drugs

By

Patients with breast cancer whose health insurance plans included prescription drug benefits were 10% more likely to start important hormonal therapy than patients who did not have prescription drug coverage.

CSF1R Inhibition May Ease Debilitating Adverse Event of Ovarian Cancer

By

Women who have ovarian cancer often develop ascites, a buildup of fluids in the abdomen. Researchers have found that ascites can be reduced with minimal side effects through inhibition of the colony-stimulating-factor-1 receptor (CSF1R).

Breakthrough Advance Announced in International Blood Cancer Drug Trial

By

Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.

New Therapy for Triple-negative Breast Cancer Shows Promise in Laboratory Studies

By

Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult-to-treat and aggressive form of the disease.

Atezolizumab Set to Change Refractory Lung Cancer Treatment

Atezolizumab Set to Change Refractory Lung Cancer Treatment

By

Atezolizumab may substantially change treatment strategies for patients with refractory lung cancer, according the first efficacy results from the POPLAR and BIRCH studies, which studied the PD-L1 antibody across treatment lines.

Two-Drug Combination Significantly Improves Overall Survival in Patients With Melanoma

By

Current results from a clinical trial comparing a combination of two targeted therapies with a single-agent treatment for advanced melanoma has shown patients are living significantly longer with the combination therapy.

Older Patients with Hodgkin Lymphoma Benefit from Treatment with Brentuximab Vedotin

By

Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.

Artificial Intelligence May Better Predict Response in Breast Cancer Treatment

Artificial Intelligence May Better Predict Response in Breast Cancer Treatment

By

Researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy drugs used to treat breast cancer: paclitaxel and gemcitabine.

Two-Drug Combination Shows Promise Against One Type of Pancreatic Cancer

Two-Drug Combination Shows Promise Against One Type of Pancreatic Cancer

By

Researchers have shown that a certain protein becomes overabundant in pancreatic neuroendocrine tumors, allowing them to thrive. They also found that pairing a synthetic compound with an existing drug provides a more effective anticancer punch than a single drug.

New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes

New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes

By

Researchers have pinpointed a novel genetic biomarker responsible for the progression of many breast and prostate cancers.

Common class of channel blockers may find a role in cancer therapy

By

Ion channel blockers, drugs commonly used to treat cardiac, neurologic, and psychiatric disorders, might prove useful in cancer therapy, according to new research.

Molecular tinkering doubles cancer drug's efficacy

By

By surrounding molecules of paclitaxel with self-assembling spheres composed of amino acids, researchers doubled tumor exposure to the drug and reduced its effects on healthy tissue.

Managing oral oncology/hematology treatments in your practice

Managing oral oncology/hematology treatments in your practice

By

An increasing number of oncology/hematology treatments will consist of oral oncolytics, and oncology programs are needed to manage the treatment of patients following these regimens.

Scientists identify key to preventing metastatic breast cancer

Scientists identify key to preventing metastatic breast cancer

By

The discovery of an enzyme that facilitates the spread of breast cancer may enable clinicians to prevent secondary cancer.

New combination is a winning strategy against glioblastoma

By

A combination approach utilizing three differing anticancer drug classes could hold the key to besting glioblastoma.

Evidence grows that melanoma drugs benefit some lung cancer patients

Evidence grows that melanoma drugs benefit some lung cancer patients

By

Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.

Nursing Evaluation, Management of Nab-Paclitaxel-Associated Peripheral Neuropathy

Nursing Evaluation, Management of Nab-Paclitaxel-Associated Peripheral Neuropathy

By

Peripheral neuropathy associated with nab-paclitaxel among chemotherapy-naïve patients can be managed by dose interruptions and modifications.

Targeted drug doubles progression-free survival in Hodgkin lymphoma

By

A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.

Childhood leukemia study reveals disease subtypes and new treatment options

Childhood leukemia study reveals disease subtypes and new treatment options

By

Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.

Drug combination suppresses growth of late-stage prostate cancer tumors

Low doses of metformin and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors.

A cancer diagnosis makes patients with diabetes less adherent to their diabetes regimen

By

According to a new study, patients with diabetes become less adherent to their diabetes medication regimen following a diagnosis of cancer.

Eribulin effective in metastatic breast cancer

By

In treatment for metastatic breast cancer, eribulin is effective as a first-, second-, or third-line chemotherapy regimen.

Assessing patency of an implanted port

Assessing patency of an implanted port

By

How should a fibrin overgrowth on an internal catheter be managed when there is no blood return from the implanted port?

Amyotrophic lateral sclerosis (ALS) drug boosts radiation effectiveness in melanoma models

By

A drug used to treat Lou Gehrig's disease has also been found to improve the effectiveness of radiation therapy when administered to laboratory models with melanoma that metastasized to the brain.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs